Spectral Diagnostics (DIAGF) 0.2750 $DIAGF
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 44.52 (+0.85), MYGN: 32.10 (-0.39), VIVO: 20.22 (-0.26), A: 47.50 (+0.24), DHR: 81.29 (+0.44), ABAX: 49.98 (+0.84), DGX: 85.45 (+1.14), TRIB: 13.01 (+0.07), HOLX: 38.18 (+0.98)
Cardiac Marker Diagnostic Testing Markets 2015
M2 - Mon Feb 16, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3jhj5/cardiac_marker) has announced the addition of the "Cardiac Marker Diagnostic Testing Markets" report to their offering. Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD. This report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies. Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers. This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets. Key Topics Covered: 1. Overview 2. The Basics of Biomarkers 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 4. Cardiovascular Disease Markers 5. Cardiac Marker Testing Development Issues 6. Business Trends in the Industry 7. Important Technology Trends 8. Company Profiles - Abbott Laboratories and SWOT Analysis - Alere and SWOT Analysis - Beckman Coulter (now part of Danaher) - Biosite, Inc. (now a brand of Alere) - bioM?rieux - CardioGenics - Chek Diagnostics - diaDexus and SWOT Analysis - Health-Chem Diagnostics (HCD) - LifeSign, LLC - Ortho-Clinical Diagnostics, Inc. and SWOT Analysis - PTS Diagnostics - PreMD, Inc. - Radiometer Medical - Randox Laboratories Ltd. - Response Biomedical - Roche Diagnostics - Sanyo Chemical Industries Ltd. - Shionogi & Co., Ltd. - Siemens Healthcare Diagnostics - Sierra Resources International - Spectral Diagnostics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iac_marker
ABT: 44.52 (+0.85), DHR: 81.29 (+0.44)
Spectral Announces Effective Date of Name Change
Marketwired - Tue Dec 16, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that its previously announced name change to "Spectral Medical Inc." will be effective December 31, 2014. This new name will reflect the Company's continuing transition into a therapeutic development company, with a strategic focus on the development and commercialization of a treatment for severe sepsis and septic shock using our Endotoxin Activity Assay and the Toraymyxin(TM) ("PMX" therapeutic.
SDI.TO: ()
Spectral Announces Normal Course Issuer Bid
Marketwired - Mon Dec 15, 7:02AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI)(OTCQX: DIAGF) a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the Toronto Stock Exchange ("TSX" has accepted Spectral's notice of intention to proceed with a normal course issuer bid through the facilities of the TSX.
SDI.TO: ()
Largest Japanese Registry Data Analysis Demonstrates Significant Reduction in Mortality Rate of Septic Patients Treated With Toraymyxin(TM)
Marketwired - Tue Nov 25, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the presentation of the largest ever analysis of Japanese registry data on the significant mortality rate reduction in patients with septic shock treated with Toraymyxin(TM) ("PMX" .The results of the study and analysis were presented at the American Society of Nephrology and support Spectral's EUPHRATES trial design.
SDI.TO: ()
Spectral Announces Third Quarter 2014 Results
Marketwired - Thu Nov 13, 7:07AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its unaudited financial results for the three and nine month periods ended September 30, 2014.
SDI.TO: ()
Spectral Provides Update on Its Path to Commercialization
Marketwired - Wed Nov 05, 7:05AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company" (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today provided an update on the Company's recent and upcoming activities, demonstrating a clear commercialization path to address the critical care needs of patients in a $3 billion market.
SDI.TO: ()
Spectral to Exhibit at the Critical Care Canada Forum
CNW Group - Wed Oct 29, 7:00AM CDT
Dr. Claudio Ronco to discuss his analysis on the importance of endotoxin removal
SDI.TO: ()
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 44.52 (+0.85), MYGN: 32.10 (-0.39), VIVO: 20.22 (-0.26), A: 47.50 (+0.24), DHR: 81.29 (+0.44), ABAX: 49.98 (+0.84), DGX: 85.45 (+1.14), TRIB: 13.01 (+0.07), HOLX: 38.18 (+0.98)
Cardiac Marker Diagnostic Testing Markets 2015
M2 - Mon Feb 16, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3jhj5/cardiac_marker) has announced the addition of the "Cardiac Marker Diagnostic Testing Markets" report to their offering. Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD. This report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies. Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers. This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets. Key Topics Covered: 1. Overview 2. The Basics of Biomarkers 3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 4. Cardiovascular Disease Markers 5. Cardiac Marker Testing Development Issues 6. Business Trends in the Industry 7. Important Technology Trends 8. Company Profiles - Abbott Laboratories and SWOT Analysis - Alere and SWOT Analysis - Beckman Coulter (now part of Danaher) - Biosite, Inc. (now a brand of Alere) - bioM?rieux - CardioGenics - Chek Diagnostics - diaDexus and SWOT Analysis - Health-Chem Diagnostics (HCD) - LifeSign, LLC - Ortho-Clinical Diagnostics, Inc. and SWOT Analysis - PTS Diagnostics - PreMD, Inc. - Radiometer Medical - Randox Laboratories Ltd. - Response Biomedical - Roche Diagnostics - Sanyo Chemical Industries Ltd. - Shionogi & Co., Ltd. - Siemens Healthcare Diagnostics - Sierra Resources International - Spectral Diagnostics, Inc. For more information visit http://www.researchandmarkets.com/research/n3...iac_marker
ABT: 44.52 (+0.85), DHR: 81.29 (+0.44)
Spectral Announces Effective Date of Name Change
Marketwired - Tue Dec 16, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that its previously announced name change to "Spectral Medical Inc." will be effective December 31, 2014. This new name will reflect the Company's continuing transition into a therapeutic development company, with a strategic focus on the development and commercialization of a treatment for severe sepsis and septic shock using our Endotoxin Activity Assay and the Toraymyxin(TM) ("PMX" therapeutic. SDI.TO: ()
Spectral Announces Normal Course Issuer Bid
Marketwired - Mon Dec 15, 7:02AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF) a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the Toronto Stock Exchange ("TSX" has accepted Spectral's notice of intention to proceed with a normal course issuer bid through the facilities of the TSX. SDI.TO: ()
Largest Japanese Registry Data Analysis Demonstrates Significant Reduction in Mortality Rate of Septic Patients Treated With Toraymyxin(TM)
Marketwired - Tue Nov 25, 7:04AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI)(OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the presentation of the largest ever analysis of Japanese registry data on the significant mortality rate reduction in patients with septic shock treated with Toraymyxin(TM) ("PMX" .The results of the study and analysis were presented at the American Society of Nephrology and support Spectral's EUPHRATES trial design. SDI.TO: ()
Spectral Announces Third Quarter 2014 Results
Marketwired - Thu Nov 13, 7:07AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its unaudited financial results for the three and nine month periods ended September 30, 2014. SDI.TO: ()
Spectral Provides Update on Its Path to Commercialization
Marketwired - Wed Nov 05, 7:05AM CST
Spectral Diagnostics Inc. ("Spectral" or the "Company"
(TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today provided an update on the Company's recent and upcoming activities, demonstrating a clear commercialization path to address the critical care needs of patients in a $3 billion market. SDI.TO: ()
Spectral to Exhibit at the Critical Care Canada Forum
CNW Group - Wed Oct 29, 7:00AM CDT
Dr. Claudio Ronco to discuss his analysis on the importance of endotoxin removal
SDI.TO: ()
